Notice of extra general meeting in SyntheticMR AB (publ)

SyntheticMR has called an extraordinary general meeting for 9 January 2026 to seek shareholder approval for a preferential rights issue to raise up to SEK 32.75m (increase share capital by SEK 661,056.9924) via issuance of up to 29,777,342 shares at SEK 1.10 per share (record date 16 Jan; subscription 20 Jan–3 Feb 2026). The company has 59,554,685 shares outstanding and no treasury shares; the Swedish Securities Council has granted Swedia Invest AB a conditional exemption from a mandatory bid obligation if Swedia’s guarantee is used and its holding rises to approximately 50.2%, a measure that requires a qualified two‑thirds majority (excluding Swedia votes) at the EGM. The transaction implies material potential dilution and a possible change of control, making the vote and guarantee outcome key drivers for shareholder value and trading in the stock.

Analysis

Market structure: The rights issue (29.777m new shares at SEK1.10 raising ~SEK32.8m) directly benefits SyntheticMR’s liquidity and Swedia Invest (as potential guarantor/allocatee) while diluting existing minority holders by ~33% of pre-issue ownership (59.55m -> ~89.33m shares). Short-term pricing power shifts to Swedia if it ends up with ~50.2% post-issue control — governance risk will weigh on free‑float liquidity and the share bid. Broader small-cap Nordic medtech peers may see sentiment pressure but larger cap names (Elekta EKTA-B.ST, Getinge GETI-B.ST) should be structurally insulated.

Risk assessment: Tail risks include Swedia using the guarantee to control >50% without a mandatory bid (conditional exemption hinges on EGM ≥66.7% support excluding Swedia), possible minority litigation, and a failed underwriting that forces deeper dilutive placements or debt draws. Immediate (days–weeks): EGM on 9 Jan and record date 16 Jan, subscription 20 Jan–3 Feb; short-term volatility will cluster around those dates. Longer-term (quarters): funding should buy ~12–18 months runway if burn ~SEK2–3m/month, otherwise another raise is likely.

Trade implications: Direct: establish a tactical short (2–4% portfolio notional) in SyntheticMR (or buy puts if liquid) into EGM/record date, target -30–50% post-dilution, stop-loss +15% above pre‑EGM price. Pair trade: long Getinge (GETI-B.ST) or Elekta (EKTA-B.ST) 2% vs short SyntheticMR equal notional to capture idiosyncratic downside; prefer weekend initiation before 16 Jan. Options: buy 1–2 month puts or put spreads around EGM and subscription windows to cap cost; sell short-dated calls on long large-cap exposure to fund hedges.

Contrarian angles: The consensus underprices the value of the SEK32.8m proceeds — if management delivers a near-term clinical/data milestone or secures institutional take-up, post-money re‑rating could recover 30–60% from depressed levels. Conversely, the exemption mechanics create governance path-dependence: if EGM rejects the Swedia allocation, fallback scenarios (underwriter dilution or default) could wipe >70% of equity value. Look for subscription uptake rates and Swedia’s actual allotment (announce within days of close) as the highest‑value datapoints for a reversal trade.

Key Decisions for Investors

• If you can short SyntheticMR directly, initiate a tactical short sized 2–4% of portfolio notional before 9 Jan EGM (or before 16 Jan record date); target a 30–50% decline post-dilution, place stop-loss at +15% above current price to limit gamma risk.
• Execute a pair trade: long 2% position in Getinge (GETI-B.ST) or Elekta (EKTA-B.ST) funded by an equal notional short in SyntheticMR to isolate idiosyncratic governance/dilution risk; rebalance after subscription close (3 Feb).
• If long SyntheticMR, subscribe pro rata in the rights issue to avoid immediate dilution (cost = SEK1.10 per new share; two rights -> one share); if unwilling to pay, sell your subscription rights immediately and redeploy proceeds.
• Buy 1–2 month put spreads on SyntheticMR (or equivalent OTC protection) expiring shortly after 3 Feb to profit from execution and allotment uncertainty; size to cover at least 50% of your short exposure to cap cost.
• Within 7 trading days after subscription close, reassess: if Swedia’s allotment <30% and subscription rate >75%, cover shorts gradually (up to 50%) — if allotment ≥50% or subscription <40%, increase short exposure by another 1–2% (high conviction downside).